GSK sees profits rise but fears slowdown in growth next year

Pharmaceutical giant GSK has revealed a jump in profits amid a boost from HIV and asthma treatments, but pointed towards slower growth next year.

It came amid the first set of results by new chief executive Luke Miels, who took over from Emma Walmsley at the turn of the year.

The new boss hailed “strong” trading over the past year and told investors it is “well placed to move forward in this next phase” for the company.

GSK reported the turnover grew by four per cent to £32.7bn in 2025, with six per cent growth in the final quarter.

Pharmaceutical giant GSK has revealed a jump in profits amid a boost from HIV and asthma treatments, but pointed towards slower growth next year. ( Photo by Andy Buchanan/PA Wire)placeholder image
Pharmaceutical giant GSK has revealed a jump in profits amid a boost from HIV and asthma treatments, but pointed towards slower growth next year. ( Photo by Andy Buchanan/PA Wire)

Growth was supported by higher demand for its speciality medicines, which saw sales increase by 17 per cent to £13.5bn.

This included 18 per cent growth for respiratory, immunology and inflammation treatments, while sales of HIV medication were up 11 per cent.

The company also suggested it has no plans to join pharmaceutical rivals in the weight-loss drug market, a week after competitor AstraZeneca partnered with a Chinese drugs firm to grow its pipeline of obesity drugs.

Mr Miels said: “On GLP-1 medication, it’s going to be very crowded.

“Medically, it is a really fascinating area, but strategically for us our focus is more on the downstream effects of obesity rather than GLP-1 products.”

GSK also said that core operating profits were up seven per cent over the past year, after accelerating to a stronger-than-expected 14 per cent in the latest quarter.

However, it told shareholders that this recent profit growth is set to moderate over 2026, predicting core operating profit growth of between seven per cent to nine per cent for the year.

Mr Miels said: “Good R&D (research and development) progress also continued, with five major product approvals achieved and several acquisitions and new partnerships completed to strengthen the pipeline further in oncology and RI&I.

“We expect this positive momentum to continue in 2026, which will be a key year of execution and operational delivery with strong focus on commercial launches and accelerating R&D.”

Related topics:
News you can trust since 1754
Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice